Home > Insider Trading > Filing (0001144204-14-022886)

Filing Details

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1270073	Intercept Pharmaceuticals Inc	ICPT	Pharmaceutical Preparations (2834)	223868459

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1353128	Gayle Barbara Duncan	C/O Intercept Pharmaceuticals, Inc. 450 W. 15Th Street, Suite 505 New York NY 10011	Chief Financial Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2014-04-11	1,504	$0.00	13,510	No	4	A	Direct
Common Stock	Acquisiton	2014-04-14	1,154	$21.50	14,664	No	4	M	Direct
Common Stock	Disposition	2014-04-14	1,154	$279.00	13,510	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	A	Direct
No	4	M	Direct
No	4	S	Direct

Reported Derivative Transactions

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Option to Purchase Common Stock	Acquisiton	2014-04-11	1,835	$0.00	1,835	$266.01
Common Stock	Option to Purchase Common Stock	Acquisiton	2014-04-11	6,650	$0.00	6,650	$266.01
Common Stock	Option to Purchase Common Stock	Disposition	2014-04-14	1,154	$0.00	1,154	$21.50

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
1,835	2024-04-11	No	4	A	Direct
6,650	2024-04-11	No	4	A	Direct
8,365	2022-11-16	No	4	M	Direct

Footnotes

The reported transaction was made pursuant to a Rule 10b5-1 plan adopted by the reporting person on March 19, 2014.
25% of the shares of restricted stock will vest on January 1, 2015, subject to the terms and conditions of the award and the Intercept Pharmaceuticals, Inc. 2012 Equity Incentive Plan (the "2012 Plan"). The remaining shares of restricted stock will vest pro rata on every subsequent three-month anniversary of the initial vesting date through January 1, 2018 (representing the vesting on each such vesting date of 6.25% of the shares of restricted stock), subject to the terms and conditions of the award and the 2012 Plan.
25% of the shares of common stock underlying this option will vest on January 1, 2015, subject to the terms and conditions of the award and the 2012 Plan. The remainder of the shares of common stock underlying this option will vest pro rata on a monthly basis after the initial vesting date through January 1, 2018 (representing the vesting on each such vesting date of approximately 2.0833% of the shares of common stock initially underlying this option), subject to the terms and conditions of the award and the 2012 Plan.
The shares underlying this option to purchase common stock will vest upon the achievement of certain regulatory milestones at future dates.
2.0833% of shares originally underlying the option vest on a monthly basis through January 1, 2016, subject to the terms and conditions of the award and the 2012 Plan.